

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 413/06, 417/06, 417/14, 263/32, 277/24, A61K 31/41, 31/44		A1	(11) International Publication Number: WO 95/01979
			(43) International Publication Date: 19 January 1995 (19.01.95)
(21) International Application Number: PCT/SE94/00663		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 5 July 1994 (05.07.94)			
(30) Priority Data: 9302332-3 6 July 1993 (06.07.93) SE			
(71) Applicant (for all designated States except US): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).		Published With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): BOAR, Bernard, Robin [GB/GB]; 25 Meadow Way, Letchworth, Herts SG3 3JB (GB). CROSS, Alan, John [GB/GB]; 2 Sheerwater Road, Woodham, Woking, Surrey GU21 5TT (GB). GRAY, Duncan, Alastair [GB/GB]; Little Cefn Farm, Hyssington, Churchstoke, Powys SY15 6EQ (GB). GREEN, Alfred, Richard [GB/GB]; 22 Laurel Drive, Southmoor, Abingdon, Oxon OX13 5DG (GB).			
(74) Agent: ASTA AKTIEBOLAG; S-151 85 Södertälje (SE).			


(54) Title: NOVEL (1-HETEROAZOLYL-1-HETEROCYCLYL)ALKANE DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE AGENTS




(1)



(a)



(b)



(c)

(57) Abstract

The present invention relates to novel heterocyclic compounds having general formula (1) wherein: X is O, S, Se, or NR₂; Y₁, Y₂, Y₃, Y₄ independently are N or CR₂; Z is O, S, Se, NR₂ or C = N; and A is (a) or (b) wherein W is O, S, NH or N-lower alkyl, with the proviso that at least one of X, Y₁, Y₂, Y₃ or Y₄ is nitrogen and that the ring (c) is not 1-methyl-2-imidazolyl; geometric and optical isomers and racemates thereof where such isomers exist, as well as pharmaceutically acceptable acid addition salts thereof and solvates thereof; having therapeutic activity, processes and intermediates for their preparation, pharmaceutical formulations containing said compounds and the medicinal use of said compounds.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Novel (1-Heteroazolyl-1-heterocyclyl)alkane Derivatives
and their Use as Neuroprotective Agents

5

Field of the Invention

The present invention relates to novel heterocyclic compounds having therapeutic activity, processes and intermediates for their preparation, pharmaceutical formulations containing said compounds and the medicinal use of said compounds.

10

Background of the Invention

There exists a large group of acute and chronic neuropsychiatric disorders for which safe and clinically effective treatments are not currently available. This diverse group of disorders encompasses a broad spectrum of initial events which are characterised by the initiation of progressive processes that sooner or later lead to neuronal cell death and dysfunction. Stroke, cerebral ischaemia, trauma or a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease are all commonly occurring conditions that are associated with neurodegeneration of the brain and/or spinal cord.

15

20

25


The ongoing search for potential treatments of neurodegenerative disorders has involved investigation of excitatory amino acid antagonists, inhibitors of lipid peroxidation, calcium channel antagonists, inhibitors of specific pathways of the arachidonic acid cascade, kappa opioid agonists, adenosine agonists, PAF antagonists and diverse other agents. At the present time there is no consensus of the relative importance of the role played by compounds belonging to any of these general classes.

30

35

In a series of papers concerned with the chemistry of pyrrole dyes, A. Treibs and co-workers (Leibig's Ann.


Chem., 1957, 602, 153-183 and 1958, 612, 242-264) have characterised a number of 1,1-dipyrrole alkenes of the following formula:



10

In a paper on the reactions of fulvenes with 1,3-dipolar compounds (Leibig's Ann. Chem., 1981, 491-501), the following compound is disclosed:

15




20

25 No pharmacological activity is associated with any of the above compounds. The substitution pattern of the above compounds places them outside the scope of the present invention.

30 European patent application EP 293220 and J. Heterocyclic Chem., 1990, 27, 1933-40 disclose 1,5-diaryl pyrazoles of formula:


35



$X = \text{O or S}$


Said compounds are related to possible anti-inflammatory agents. Such activity requires the presence of the 1,5-diaryl substituents, a feature which excludes these compounds from the scope of the present invention.

In patent application EP 351 194 compounds of the general formula:




wherein Q is thiazolyl, Ar¹ is aryl of up to 10 carbon atoms, Ar² is 6-membered aryl, including pyridyl, X is O, S, SO, SO₂ or NH and A is a direct link to X or is (1-6C)alkylene, (3-6C)alkenylene, (3-6C)alkynylene or cyclo(3-6C)alkylene are disclosed as 5-lipoxygenase inhibitors. The substituent Ar¹-A-X is not included within the scope of R¹ in claim 1 of the present invention.

Monatsh. Chem. 1987, 118, 1031-1038, discloses a compound of formula:



and J. Heterocyclic Chem., 1989, 26, 1869-1873 describes compounds of formulae



10 No pharmacological activity is associated with the compounds in either of these two papers. These three specific compounds are deleted from the scope of the present invention by a disclaimer in claim 1.


15 In Zh.Obshch.Khim., 1962, 32, 2664-2670 (Chem.Abs. 58: 9057h), 1-(4-pyridyl)-1-(2-thiazolyl)ethanol is described. In Zh.Obshch.Khim., 1963, 33, 825-828 (Chem.Abs. 59: 8722a), 1-(2-pyridyl)-1-(2-thiazolyl)-ethanol is described. No pharmacological activity is associated with either of these two compounds. These two
20 specific compounds are deleted from the scope of the present invention by a disclaimer in claim 1.

The present invention

25 A primary objective of the present invention is to provide structurally novel heterocyclic compounds which by virtue of their pharmacological profile are expected to be of value in the treatment of acute and chronic neuropsychiatric disorders characterised by progressive processes that sooner or later lead to neuronal cell
30 death and dysfunction. Such disorders include stroke; cerebral ischaemia; dysfunctions resulting from brain and/or spinal trauma; hypoxia and anoxia, such as from drowning, and including perinatal and neonatal hypoxic asphyxial brain damage; multi-infarct dementia; AIDS
35 dementia; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's chorea, epilepsy, multiple sclerosis and amyotrophic lateral

sclerosis; brain dysfunction in connection with surgery involving extracorporeal circulation or in connection with brain surgery, including endarterectomy of the carotid arteries; and CNS dysfunctions as a result of exposure to neurotoxins or radiation. This utility is manifested, for example, by the ability of these compounds to inhibit delayed neuronal death in the gerbil bilateral occlusion model of ischaemia.

The present invention relates to a compound having the general formula (1)



wherein:

X is O, S, Se or NR₂;

Y₁, Y₂, Y₃, Y₄ independently are N or CR₂;


Z is O, S, Se, NR₂ or C=N;

R₁ is one or more groups selected from H, lower alkyl, lower acyl, halogen, lower alkoxy or CF₃ or R₁ and the

ring  together represent a fused benzo ring

optionally further substituted;

R₂ is H, lower alkyl, lower alkoxy-lower alkyl, hydroxy-lower alkyl, lower acyloxy-lower alkyl, aryl-lower alkyl or CF₃ and when more than one R₂ groups are present these may be selected independently;




5 wherein W is O, S, NH or N-lower alkyl,

R₃ is H, lower alkyl or lower acyl,

R₄ is lower alkyl, aryl-lower alkyl,
cyclopropyl or lower perfluoroalkyl,
or R₃ and R₄ together form a ring


10



R₅ and R₆ independently are H, lower alkyl,
or aryl-lower alkyl;

15

with the proviso that at least one of X, Y₁, Y₂, Y₃ or Y₄
is nitrogen and that the ring



is not 1-methyl-2-imidazolyl;

20

geometrical and optical isomers and racemates thereof
where such isomers exist, as well as pharmaceutically
acceptable acid addition salts thereof and solvates
thereof;

25

and with the proviso that the following five compounds
are excluded:

1-(3-indolyl)-1-(2,5-dimethyl-3-pyrrolyl)ethene;

1-(1-methyl-2-indolyl)-1-(1-methyl-2-pyrrolyl)ethene;

1-(1-methyl-2-indolyl)-1-(1-methyl-2-pyrrolyl)ethanol;

30

1-(4-pyridyl)-1-(2-thiazolyl)ethanol;


1-(2-pyridyl)-1-(2-thiazolyl)ethanol.

35

The expression "pharmaceutically acceptable acid addition
salts" is intended to include but is not limited to such
salts as the hydrochloride, hydrobromide, hydroiodide,
nitrate, hydrogen sulphate, dihydrogen phosphate,
ethanedisulphonate, mesylate, fumarate, maleate and

succinate.

Preferred embodiments of this invention relate to compounds having the general formula (2)




10 wherein:

X is O or S;

and A, Z, R₁ and R₂ are as previously defined above.

15 More preferred embodiments of this invention relate to compounds having the general formula (3)




25 wherein:

X and Z independently are O or S;

W is O;

and R₁, R₂, R₃, R₄ are as previously defined above;

30 and to compounds having the general formula (4)



wherein:

X and Z independently are O or S;

and R₁, R₂, R₅ and R₆ are as previously defined above.

5

Analogous compounds wherein X is Se, for example, 1-(3-furyl)-1-(4-methyl-5-selenazolyl)ethanol and 1-(2-selenazolyl)-1-(3-thienyl)ethanol, are specifically included within the scope of the invention.

10

Throughout the specification and the appended claims, a given chemical formula or name shall encompass all geometrical and optical isomers and racemates thereof where such isomers exist, as well as pharmaceutically acceptable acid addition salts thereof and solvates thereof such as for instance hydrates.

15

The following definitions shall apply throughout the specification and the appended claims.

20

Unless otherwise stated or indicated, the term "lower alkyl" denotes a straight or branched alkyl group having from 1 to 6 carbon atoms. Examples of said lower alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl and straight- and branched-chain pentyl and hexyl.

25

Unless otherwise stated or indicated, the term "lower perfluoroalkyl" denotes a straight or branched alkyl group having from 1 to 4 carbon atoms fully substituted by fluorine. Examples of said lower perfluoroalkyl groups include trifluoromethyl, pentafluoroethyl and heptafluoroisopropyl.

30

Unless otherwise stated or indicated, the term "lower acyl" denotes a straight or branched acyl group having from 1 to 6 carbon atoms. Examples of said lower acyl

35

include formyl, acetyl, propionyl, iso-butyryl, valeryl, and pivaloyl.

5 Unless otherwise stated or indicated, the term "lower alkoxy" denotes a straight or branched alkoxy group having from 1 to 6 carbon atoms. Examples of said lower alkoxy include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, t-butoxy and straight- and branched-chain pentoxy and hexoxy.

10

Unless otherwise stated or indicated, the term "hydroxy-lower alkyl" denotes a lower alkyl group as defined above substituted by a hydroxy group. Examples of said hydroxy-lower alkyl include hydroxymethyl, 1-hydroxyethyl and 2-hydroxyethyl.

15

Unless otherwise stated or indicated, the term "lower acyloxy-lower alkyl" denotes a lower alkyl group as defined above substituted by an oxygen atom which itself bears a lower acyl group as defined above. Examples of said lower acyloxy-lower alkyl include acetoxymethyl, propionyloxymethyl, 1-acetoxyethyl and 2-acetoxyethyl.

20

Unless otherwise stated or indicated, the term "halogen" shall mean fluorine, chlorine, bromine or iodine.

25

Unless otherwise stated or indicated, the term "lower alkoxy-lower alkyl" denotes a lower alkyl group as defined above substituted by a lower alkoxy group as defined above. Examples of said lower alkoxy-lower alkyl include methoxymethyl, ethoxymethyl, methoxyethyl and ethoxyethyl.

30

Unless otherwise stated or indicated, the term "aryl" denotes a phenyl, naphthyl, furyl, thienyl, pyridyl or pyrrolyl group, itself optionally substituted.

35

Unless otherwise stated or indicated, the term "aryl-lower alkyl" denotes a lower alkyl group as defined above substituted by an aryl group as defined above. Examples of said aryl-lower alkyl include benzyl, phenethyl, phenylpropyl, 4-fluorophenylmethyl, furfuryl, 3-furylmethyl, tolylethyl and thenyl.

Unless otherwise stated or indicated, the term "fused benzo ring" denotes a fully unsaturated five-membered heterocyclic ring containing one heteroatom fused onto a benzene ring. Examples of said fused benzo ring include benzofuranyl, benzo[b]thienyl and indolyl.

Among the most preferred compounds of formula (1) according to the present invention are:

- 1-(3-furyl)-1-(4-methyl-5-oxazolyl)ethanol;
- 1-(4-methyl-5-oxazolyl)-1-(3-thienyl)ethanol;
- 1-(3-furyl)-1-(4-methyl-5-thiazolyl)ethanol;
- 1-(2,4-dimethyl-5-oxazolyl)-1-(3-furyl)ethanol;
- 1-(2,4-dimethyl-5-thiazolyl)-1-(3-furyl)ethanol;
- 1-(4-methyl-5-thiazolyl)-1-(3-thienyl)ethanol;
- 1-(2-ethyl-4-methyl-5-oxazolyl)-1-(3-thienyl)ethanol;
- 1-(2,5-dimethyl-4-oxazolyl)-1-(3-furyl)ethanol;
- 1-(4-methyl-5-thiazolyl)-1-(2-thienyl)ethanol;
- 1-(5-thiazolyl)-1-(3-thienyl)ethanol;
- 1-(3-furyl)-1-(4-methyl-5-oxazolyl)ethene;
- 1-(3-furyl)-1-(4-methyl-5-oxazolyl)-1-propene;
- 1-(2,4-dimethyl-5-oxazolyl)-1-(3-furyl)ethene;
- 1-(2-furyl)-1-(4-methyl-5-oxazolyl)ethanol;
- 1-(2-thiazolyl)-1-(2-thienyl)ethanol;
- 1-(2-thiazolyl)-1-(3-thienyl)ethanol;
- 1-(3-furyl)-1-(4-methyl-2-oxazolyl)-2,2,2-trifluoroethanol;
- 1-(4-methyl-2-oxazolyl)-1-(3-thienyl)ethanol;
- 1-(2,4-dimethyl-5-oxazolyl)-1-(3-furyl)-2,2,2-trifluoroethanol;

trifluoroethanol;


1-(3-furyl)-1-(4-methyl-5-oxazolyl)ethylamine;

1-(2-thiazolyl)-1-(3-thienyl)ethylamine;

- 5 and pharmaceutically acceptable acid addition salts or solvates thereof.


The present invention also relates to processes for preparing the compound having formula (1). Throughout the following general description of such processes it is to be understood that, where appropriate, suitable protecting groups will be added to, and subsequently removed from, the various reactants and intermediates in a manner that will be readily understood by one skilled in the art of organic synthesis. Conventional procedures for using such protecting groups are described, for example, in "Protective Groups in Organic Synthesis", T.W. Greene, Wiley-Interscience, New York, 1981.

- 20 Said compound wherein A is





may be prepared by


- (a) reacting a compound of general formula (5) with an organometallic derivative of general formula (6)



- or (b) reacting a compound of general formula (7) with an organometallic derivative of general formula (8)



10 or (c) reacting a compound of general formula (9) with an organometallic derivative of general formula R_4M




20 and quenching the reaction mixture with a proton source (R_3 is H) or an alkylating (R_3 is lower alkyl) or acylating (R_3 is lower acyl) reagent;

or (d), particularly in cases where R_4 is perfluoroalkyl, reacting a compound of general formula (9) with a silyl derivative of general formula R_4SiMe_3 .

25

Alternatively, the compound of formula (1)



obtained as above and then converted into the compound wherein R_3 is lower alkyl or lower acyl.

35 The processes (a), (b) or (c) can be achieved for example, by reacting together a ketone of structure (5) or (7) or (9) with a preformed organometallic derivative (6) or (8) or R_4M respectively in a suitable anhydrous

or mixtures thereof. Said reaction should be conducted at a suitable temperature, normally between -100°C and $+50^{\circ}\text{C}$ and preferably under an inert atmosphere, normally nitrogen or argon. In a specific variation, a solution of the ketone of structure (5) or (7) or (9) in anhydrous diethylether or tetrahydrofuran is added dropwise to the organometallic derivative (6) or (8) or R_4M respectively in anhydrous diethylether or tetrahydrofuran or hexane or mixtures thereof at a temperature of about -50°C to -78°C and under an atmosphere of nitrogen. After a suitable period of time the reaction mixture is allowed to warm to room temperature and then quenched by the addition of water or a lower alcohol. The required product (1)

wherein A is $\text{C} \begin{array}{l} \text{OH} \\ \text{R}_4 \end{array}$ may then be isolated and purified and characterised using standard techniques.


The process (d) can be achieved, for example, by treating a solution of the ketone (9) and the silyl derivative R_4SiMe_3 in a suitable anhydrous solvent such as diethylether or tetrahydrofuran with tetrabutylammonium fluoride. Said reaction should be conducted at a suitable temperature, normally between -100°C and $+50^{\circ}\text{C}$ and preferably under an inert atmosphere, normally nitrogen or argon. After a suitable period of time the reaction mixture is allowed to come to room temperature and is then treated with 6M hydrochloric acid. The

required product (1) wherein A is $\text{C} \begin{array}{l} \text{OH} \\ \text{R}_4 \end{array}$ may then be isolated and purified and characterised using standard techniques.

Ketones of general formula (5) or (7) or (9) are either compounds which are commercially available or have been previously described in the literature, or compounds

previously described in the literature, or compounds which can be prepared by the straightforward application of known methods.

- 5 Thus, the present invention also refers to some new intermediates, namely 4 or 5 acyl substituted compounds of the general formulas (5) and (9), respectively:



15 wherein X is O, S or Se;

Y₁ is C-H, C-lower alkyl or C-CF₃;

Y₂ is N;

either Y₃ or Y₄ is CR₂ and the acyl group is attached to the other of these positions;

20 R₄ is C₂ to C₆ alkyl or perfluoroalkyl;

and R₁, R₂ and Z are as defined above

with the provisos that when X is O, the acyl group is not attached to Y₃ and that the following four compounds are excluded:

25 ethyl 4-thiazolyl ketone;

tert-butyl 5-thiazolyl ketone;

tert-butyl 5-oxazolyl ketone;

tert-butyl 4-tert-butyl-2-methyl-5-oxazolyl ketone.

30 In the organometallic derivatives of general formula (6) or (8) or R₄M, M represents a metallic residue such as Li or Mg-halogen. Such compounds are either commercially available or have been previously described in the literature, or can be prepared by the straightforward application of known methods of organometallic chemistry.

35

Silyl derivatives of formula R₄SiMe₃ are either


commercially available, for example, CF_3SiMe_3 , or have been previously described in the literature or can be prepared by the straightforward application of known methods.

5

Compounds of formula (1) wherein A is $\text{C}=\text{C}$ $\begin{matrix} \text{R}_5 \\ \text{R}_6 \end{matrix}$ may be prepared by

10

(a) elimination of HWR_3 from a compound of formula (1) wherein



15

or (b) by using a compound of general formula (9) as the substrate for a standard alkene forming reaction such as the Wittig reaction, the Peterson reaction or the McMurry reaction.

20


The process (a) can be achieved, for example, by treatment of a solution of a compound of formula (1)



25

in a suitable inert solvent with an acid or a base or a reagent such as thionyl chloride or phosphorus oxychloride. Said reaction should be conducted at a suitable temperature, normally between -20°C and the reflux temperature of the solvent. In a preferred variation, a solution of a compound of formula (1)

30



35

dichloromethane or chloroform at 0°C to 10°C is treated with an acid such as anhydrous hydrogen chloride or p-toluenesulphonic acid, or with thionyl chloride. The reaction is then allowed to proceed at ambient temperature or above. The required product (1) wherein

A is $\text{C}=\text{C}$ $\begin{matrix} \text{R}_5 \\ \text{R}_6 \end{matrix}$ may then be isolated and purified and
 5 characterised using standard techniques.

Compounds of formula (1) wherein A is C $\begin{matrix} \text{NHR}_3 \\ \text{R}_4 \end{matrix}$ may
 be prepared by

10

(a) using a compound of general formula (1) wherein

A is C $\begin{matrix} \text{OR}_3 \\ \text{R}_4 \end{matrix}$ or $\text{C}=\text{C}$ $\begin{matrix} \text{R}_5 \\ \text{R}_6 \end{matrix}$ as the substrate for a
 15 Ritter reaction,

or (b) by using a compound of general formula (1) wherein

20

A is C $\begin{matrix} \text{OH} \\ \text{R}_4 \end{matrix}$ as the substrate for a Mitsunobu-type
 reaction

25

or (c) reacting a compound of general formula (1) wherein

A is C $\begin{matrix} \text{OR}_3 \\ \text{R}_4 \end{matrix}$ with trimethylsilylazide, Me_3SiN_3 , in the
 30 presence of a Lewis acid such as boron trifluoride
 diethyletherate to give an azide of formula (1) wherein

A is C $\begin{matrix} \text{N}_3 \\ \text{R}_4 \end{matrix}$, and then reducing said azide using, for
 example, hydrogen in the presence of a palladium or
 35 platinum catalyst.

Some compounds of general formula (1) contain an

asymmetric centre and can thus exist in enantiomeric forms. These enantiomers may be separated using methods that will be well known to one skilled in the art. Such methods include, for example,

5

(i) direct separation by means of chiral chromatography, for example, by HPLC using a chiral column;

10

or (ii) recrystallisation of the diastereomeric salts formed by reacting the base (1) with an optically active acid;

15


or (iii) derivatization of the compound of formula (1) by reaction with an optically active reagent, separation of the resultant diastereoisomeric derivatives by, for example, crystallisation or chromatography, followed by regeneration of the compound of formula (1).

20

Alternatively, compounds of formula (1) may be obtained directly in an optically active form by using a chemical or enzymatic based method of asymmetric synthesis.

Some compounds of general formula (1) wherein A is

25



30

can exist as E and Z (trans and cis) isomers. Such isomers may be separated using standard techniques, for example, crystallisation or chromatography, that will be readily apparent to one skilled in the art.

Pharmacology

35

The neuroprotective properties of the compounds of formula (1) are exemplified by their ability to inhibit delayed neuronal death in the gerbil bilateral occlusion model of ischaemia.

Animals used were male Mongolian gerbils (60-80g). Drugs were dissolved in isotonic saline containing dimethylsulphoxide.

5 Ischaemia was induced in the gerbils by 5 minute occlusion of both carotid arteries following the procedure described by R. Gill, A.C. Foster and G.N. Woodruff, J. Neuroscience. 1987, 7, 3343-3349. Body temperature was maintained at 37°C throughout.

10 Restoration of blood flow after occlusion was checked visually and the animals were allowed to survive for 4 days. The extent of neuronal degeneration in the hippocampus was then assessed. The test compounds were administered (i.p.) as a single dose 60 minutes following

15 occlusion. No administration was made prior to the occlusion. The effectiveness of the compounds of formula (1) in decreasing damage to the CA1/CA2 hippocampal neurones in gerbils following ischaemic insult clearly illustrates the usefulness of these compounds in

20 preventing neurodegeneration. These compounds are therefore expected to be of value in the treatment of acute and chronic neuropsychiatric disorders characterised by progressive processes that sooner or later lead to neuronal cell death and dysfunction.

25

Pharmaceutical Formulations

The administration in the novel method of treatment of this invention may conveniently be oral, rectal, topical or parenteral at a dosage level of, for example, about

30 0.01 to 1000 mg/kg, preferably about 1.0 to 500 mg/kg and especially about 5.0 to 200 mg/kg and may be administered on a regimen of 1 to 4 doses or treatments per day. The dose will depend on the route of administration, preferred routes being oral or intravenous

35 administration. It will be appreciated that the severity of the disease, the age of the patient and other factors normally considered by the attending physician will

influence the individual regimen and dosage most appropriate for a particular patient.

5 The pharmaceutical formulations comprising the compound of this invention may conveniently be tablets, pills, capsules, syrups, powders or granules for oral administration; sterile parenteral solutions or suspensions for parenteral administration; suppositories for rectal administration; or suitable topical
10 formulations. Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described, for example, in "Pharmaceuticals - The Science of Dosage Form Design", M. E. Aulton, Churchill Livingstone, 1988.

15 To produce pharmaceutical formulations containing a compound according to the present invention in the form of dosage units for oral application the active substance may be admixed with an adjuvant/a carrier e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato
20 starch, corn starch or amylopectin, cellulose derivatives, a binder such as gelatine or polyvinylpyrrolidone, and a lubricant such as magnesium stearate, calcium stearate, polyethylene glycol, waxes, paraffin, and the like, and then compressed into tablets. If coated
25 tablets are required, the cores, prepared as described above, may be coated with a concentrated sugar solution which may contain e.g. gum arabic, gelatine, talcum, titanium dioxide, and the like. Alternatively, the tablet
30 can be coated with a polymer known to the man skilled in the art, dissolved in a readily volatile organic solvent or mixture of organic solvents. Dyestuffs may be added to these coatings in order to readily distinguish between tablets containing different active substances or
35 different amounts of the active compounds.

For the preparation of soft gelatine capsules, the active

substance may be admixed with e.g. a vegetable oil or polyethylene glycol. Hard gelatine capsules may contain granules of the active substance using either the above mentioned excipients for tablets e.g. lactose, 5 saccharose, sorbitol, mannitol, starches (e.g. potato starch, corn starch or amylopectin), cellulose derivatives or gelatine. Also liquids or semisolids of the drug can be filled into hard gelatine capsules.

10 Dosage units for rectal application can be solutions or suspensions or can be prepared in the form of suppositories comprising the active substance in admixture with a neutral fatty base, or gelatine rectal capsules comprising the active substance in admixture 15 with vegetable oil or paraffin oil.

Liquid preparations for oral application may be in the form of syrups or suspensions, for example solutions containing from about 0.02% to about 20% by weight of the 20 active substance herein described, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol. Optionally such liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethylcellulose as a thickening agent or other 25 excipients known to the man in the art.

Solutions for parenteral applications by injection can be prepared in an aqueous solution of a water-soluble pharmaceutically acceptable salt of the active substance, 30 preferably in a concentration of from about 0.5% to about 10% by weight. These solutions may also contain stabilizing agents and/or buffering agents and may involve the use of surface acting agents to improve solubility. They may conveniently be provided in various 35 dosage unit ampoules.

The necessary starting materials for all Preparations and

Examples were purchased commercially except as follows:

4-methyl-5-oxazolecarbonyl chloride (Indian J. Chem.,
Sect. B. 1985, 24B, 535-8);

5

2,4-dimethyl-5-oxazolecarbonyl chloride (EP 154 132);

5-acetyl-4-methyloxazole (Chem. Ber., 1960, 93, 1998-
2001);

10

5-acetyl-4-methylthiazole (J. Agr. Food Chem., 1974, 22,
264-9);

15

5-acetyl-2,4-dimethyloxazole (Chem. Ber., 1960, 93, 1998-
2001);

4-acetyl-2,5-dimethyloxazole (J. Am. Chem. Soc., 1975,
97, 6484-6491);

20

5-acetyl-3-methylisoxazole and 3-acetyl-5-methylisoxazole
(J. Org. Chem., 1989, 54, 2646-2650).

PREPARATION 1

N-Methoxy-N-methyl-4-methyl-5-oxazolecarboxamide

25

4-Methyl-5-oxazolecarbonyl chloride (15g) and N,O-
dimethylhydroxylamine hydrochloride (11g) in dry
chloroform (100ml) were cooled to 0°C and dry pyridine
(28.5g) was added. The mixture was allowed to warm to
room temperature. After 30 minutes aqueous sodium
hydrogen carbonate was added and the organic layer
separated. The aqueous layer was extracted with
dichloromethane. The combined organic layers were
washed, dried and evaporated. The residue was purified
by flash chromatography to yield the title compound as a
white solid. M.p. 59-60°C.

35

¹H Nmr (CDCl₃) 2.5, 3.34 and 3.82 (each 3H, s) and 7.86

(1H, s) ppm.

Found: C, 49.0; H, 5.6; N, 16.4. $C_7H_{10}N_2O_3$ requires C, 49.4; H, 5.9; N, 16.5%

5

PREPARATION 2

N-Methoxy-N-methyl-2,4-dimethyl-5-oxazolecarboxamide

Starting with 2,4-dimethyl-5-oxazolecarbonyl chloride and following the general method of Preparation 1, the title compound was obtained as a waxy solid.

10

1H Nmr ($CDCl_3$) 2.42, 2.5, 3.32 and 3.8 (each 3H, s) ppm.

PREPARATION 3

3-Furyl 4-Methyl-5-oxazolyl Ketone

15

3-Bromofuran (2.5g) in dry diethylether was stirred and cooled to $-70^\circ C$ under an atmosphere of dry nitrogen and n-butyllithium (2.5M solution in hexane, 6.8ml) was added dropwise. After 30 minutes, N-methoxy-N-methyl-4-methyl-5-oxazolecarboxamide (2.89g) in dry diethylether was added dropwise. After a further 30 minutes the mixture was allowed to warm to room temperature. Ethanol (5ml) was added followed by saturated aqueous sodium chloride. The mixture was extracted with dichloromethane and the material thus obtained was purified by flash chromatography to give the title compound. M.p. $82-83.5^\circ C$.

20

25

1H Nmr ($CDCl_3$) 2.62 (3H, s), 7.01, 7.52, 7.95 and 8.42 (each 1H) ppm.

30

Found: C, 60.8; H, 4.4; N, 8.0. $C_9H_7NO_3$ requires C, 61.0; H, 4.0; N, 7.9%

PREPARATION 4

5-Acetyl-2-ethyl-4-methyloxazole

35

3-Chloropentane-2,4-dione (46.5g), propionamide (50g) and propionic acid (151g) were heated at $145^\circ C$ for 5 hours. The mixture was cooled to room temperature, then basified

to pH 10 using 10M aqueous sodium hydroxide, and extracted with dichloromethane. The combined extracts were washed with brine, dried and the solvent removed to leave a brown oil which was purified by vacuum distillation, b.p. 70°C at 2 mbar.

¹³C Nmr (CDCl₃) 10.6, 13.4, 21.6, 27.2, 144.7, 145.0, 166.4 and 187.2 ppm.

10

PREPARATION 5

4-Methyl-5-propionyloxazole

N-methoxy-N-methyl-4-methyl-5-oxazolecarboxamide (5g) in dry tetrahydrofuran at -40°C was stirred under a nitrogen atmosphere and ethylmagnesium bromide (1M solution in tetrahydrofuran, 35ml) was added dropwise. After 30 minutes the mixture was allowed to warm to room temperature and then stirred for a further 1 hour. Aqueous sodium hydrogen carbonate was added, the organic layer was separated and the aqueous layer was extracted with diethylether. The material thus obtained was purified by flash chromatography to yield a pale yellow liquid which solidified on cooling.

¹H Nmr (CDCl₃) 1.22 (3H, t), 2.53 (3H, s), 2.85 (2H, q) and 7.84 (1H, s) ppm.

25

PREPARATION 6

2,4-Dimethyl-5-propionyloxazole

Following the general method of Preparation 5 but starting with N-methoxy-N-methyl-2,4-dimethyl-5-oxazolecarboxamide, the title compound was obtained as a low-melting solid.

¹H Nmr (CDCl₃) 1.21 (3H, t), 2.48 and 2.52 (each 3H, s) and 2.84 (2H, q) ppm.

35

PREPARATION 7

4-Methyl-2-trimethylsilylthiazole

n-Butyllithium (2.5M solution in hexane, 1.1 equivalents) was added dropwise to a solution of 4-methylthiazole (1.0 equivalent) in dry diethyl ether at -70°C under an atmosphere of dry nitrogen. After 30 minutes, trimethylsilylchloride (1.0 equivalent) was added dropwise. The mixture was allowed to warm to room temperature and was then quenched by the addition of saturated aqueous sodium hydrogen carbonate. Work-up in the normal fashion and vacuum distillation then gave the title compound. B.p. 42°C at 1mm Hg.

PREPARATION 8

15 2,4-Dimethyl-5-oxazolyl 3-Furyl Ketone

Following the method of Preparation 3 but using N-methoxy-N-methyl-2,4-dimethyl-5-oxazolecarboxamide, the title compound was prepared. M.p. 73.5-74.5°C.

20 Found: C, 62.6; H, 4.7; N, 7.45. $C_{10}H_9NO_3$ requires C, 62.8; H, 4.75; N, 7.3%

PREPARATION 9

Cyclopropyl 4-Methyl-5-oxazolyl Ketone

25 Following the method of Preparation 3 but using cyclopropyl magnesium bromide, the title compound was obtained.

1H Nmr ($CDCl_3$) 1.06 and 1.25 (each 2H, m), 2.53 (3H, s), 2.65 (1H, m) and 7.91 (1H, s) ppm.

PREPARATION 10

t-Butyl 2,4-Dimethyl-5-oxazolyl Ketone

35 Starting with N-methoxy-N-methyl-2,4-dimethyl-5-oxazolecarboxamide and t-butyllithium and following the general method of Preparation 3, the title compound was prepared.

¹³C Nmr (CDCl₃) 13.7, 13.9, 26.0, 43.3, 144.2, 147.1, 160.8 and 195.1 ppm.

PREPARATION 11

5 2,4-Dimethyl-5-oxazolyl 2-Propyl Ketone

Starting with N-methoxy-N-methyl-2,4-dimethyl-5-oxazolecarboxamide and 2-propyl magnesium chloride and following the general method of Preparation 3, the title compound was obtained.

10

¹³C Nmr (CDCl₃) 13.3, 13.9, 17.9, 36.8, 144.3, 145.3, 161.6 and 193.8 ppm.

PREPARATION 12

15 3-Trifluoroacetylfuran

3-Bromofuran (20g) was added to a solution of n-butyllithium (2.5M in hexanes, 60ml) in diethyl ether (200ml) at -70°C. After 30 minutes, ethyl trifluoroacetate (28.6g) was added slowly. After a further 1 hour the mixture was allowed to warm to room temperature and was then left to stir overnight. 1M Hydrochloric acid (100ml) was added and the mixture stirred for 5 minutes. The organic layer was separated, washed, dried and evaporated. The residue was distilled to give the title compound. B.p. 118°C.

20

25

¹³C Nmr (CDCl₃) 109.0, 116.2 (q, J 290Hz), 121.0, 144.9, 150.6 and 175.5 (q, J 37Hz) ppm.

30

PREPARATION 13

3-Trifluoroacetylthiophene

The title compound was prepared following the method of Preparation 12 but using 3-bromothiophene. B.p. 48°C at 10 mBar.

35

¹³C Nmr (CDCl₃) 116.8 (q, J 290Hz), 127.4, 127.9, 134.5, 137.3 and 174.8 (q, J 37Hz) ppm.

PREPARATION 14

5-Acetyl-2-amino-4-trifluoromethylthiazole

Hydroxy(tosyloxy)iodobenzene (78.5g) was added to a solution of 1,1,1-trifluoropentane-2,4-dione in acetonitrile (500ml). The mixture was heated under reflux for 45 minutes, then cooled, and thiourea (15.2g) was added. The mixture was heated under reflux for 4 hours and then left to stand overnight. Evaporation and crystallisation of the residue from dichloromethane gave the title compound.

^{13}C Nmr (d_6 -DMSO) 29.5, 120.1, (q, J 270 Hz), 125.5, 141.1, (q, J 35Hz), 170.3 and 187.2 ppm.

PREPARATION 15

5-Acetyl-4-trifluoromethylthiazole

The product from Preparation 14 (7g) was added to a mixture of nitric acid (69%, 10ml) and phosphoric acid (85%, 48ml). The suspension was stirred and cooled to -20°C and sodium nitrite (3.6g) in water (30ml) was added dropwise. After a further 30 minutes at -20°C , hypophosphorous acid (50%, 19.5ml) was added dropwise. After 15 minutes the mixture was allowed to warm to 0°C . After 1 hour the mixture was basified using 40% aqueous sodium hydroxide and extracted with dichloromethane. The extracts were washed, dried and evaporated and the residue was purified by flash chromatography to give the title compound.

^{13}C Nmr (CDCl_3) 30.3, 120.2 (q, J 270Hz), 140.2, 144.0 (q, J 38Hz), 155.6 and 189.2 ppm.

PREPARATION 16

4-Bromo-1,3,5-trimethylpyrazole

4-Bromo-3,5-dimethylpyrazole (10g) in dry dimethylformamide (50ml) was added to a stirred suspension of sodium hydride (1.8g) in dry

dimethylformamide at 0°C. When the evolution of hydrogen was complete, iodomethane (8.9g) was added dropwise. The mixture was allowed to warm to room temperature and after 30 minutes saturated aqueous sodium hydrogen carbonate (5ml) was added. Following evaporation under high vacuum, the residue was purified by column chromatography to give the title compound.

¹H Nmr (CDCl₃) 2.2, 2.22 and 3.73 (each 3H, s) ppm.

PREPARATION 17

4-Methyl-2-trifluoroacetyloxazole

1-Trifluoroacetylimidazole (10g) was added dropwise to 4-methyl-2-trimethylsilyloxazole (J. Chem. Soc., Chem. Commun., 1984, 258) (9.95g) in diethyl ether (100ml) at 0°C under an atmosphere of dry nitrogen. The mixture was stirred overnight at room temperature. Water was added and the organic layer was separated, washed, dried and evaporated. Flash chromatography gave the title compound.

¹³C Nmr (d₆-DMSO) (as hydrate) 11.0, 89.5, (q, J 33Hz), 122.3 (q, J 287Hz), 136.0, 136.1 and 158.6 ppm.

PREPARATION 18

5-Methoxymethyl-4-methylthiazole

4-Methyl-5-thiazolecarbaldehyde (J. Amer. Chem. Soc., 1982, 104, 4934-4943) was reduced using aluminium isopropoxide in 2-propanol. The resulting alcohol was treated with sodium hydride in dimethoxyethane and iodomethane was added. Distillation gave the title compound.

¹³C Nmr (CDCl₃) 14.2, 57.0, 64.9, 127.2, 149.9 and 150.5 ppm.

EXAMPLE 1

1-(3-Furyl)-1-(4-methyl-5-oxazolyl)ethanol

5 a) 3-Bromofuran (7.6g) in dry tetrahydrofuran (25ml) at -70°C under a nitrogen atmosphere was treated dropwise with n-butyllithium (2.5M solution in hexane, 20.8ml). After 30 minutes, 5-acetyl-4-methyloxazole (5g) was added dropwise. After a further 30 minutes at -70°C, the reaction mixture was allowed to warm to room temperature and then stirred for 30 minutes. Ethanol (12ml) was
10 added and the reaction mixture was then poured into saturated aqueous sodium chloride and extracted with dichloromethane. The product thus obtained was purified by chromatography on silica gel or neutral alumina. Crystallisation from diethylether then gave 1-(3-furyl)-
15 1-(4-methyl-5-oxazolyl)ethanol as a white solid, m.p. 102-103°C.

¹H Nmr (CDCl₃) 1.9 (3H, s), 2.1 (3H, s), 6.36 (1H, q), 7.37-7.41 (2H, m) and 7.67 (1H, s) ppm.
20 ¹³C Nmr (CDCl₃) 12.4, 28.9, 68.4, 108.8, 130.7, 131.1, 138.8, 143.5, 148.4 and 149.0 ppm.

Found: C, 62.3; H, 5.7; N, 7.3. C₁₀H₁₁NO₃ requires C, 62.2; H, 5.7; N, 7.25%

25

b) 3-Furyl 4-methyl-5-oxazolyl ketone (1g) in dry diethylether (15ml) at -70°C under a nitrogen atmosphere was treated dropwise with methyllithium (1.5M solution in diethylether, 4.1ml). After 45 minutes the reaction
30 mixture was allowed to warm to room temperature and ethanol (2ml) was added. The mixture was poured into saturated aqueous sodium chloride and extracted with dichloromethane. Chromatography and crystallisation then gave 1-(3-furyl)-1-(4-methyl-5-oxazolyl)ethanol identical
35 to the material obtained in (a) above.

EXAMPLE 2

1-(4-Methyl-5-oxazolyl)-1-(3-thienyl)ethanol

3-Bromothiophene (4.23g) in diethylether (10ml) was added dropwise to n-butyllithium (2.5M solution in hexane, 10.4ml) in dry diethylether (20ml) at -70°C under a nitrogen atmosphere. After 3 hours 5-acetyl-4-methyloxazole (2.5g) in diethylether (10ml) was added dropwise. After a further 2.5 hours at -70°C, the mixture was allowed to warm to room temperature and then left overnight. The mixture was poured into water and extracted with ether. The product thus obtained was crystallised from diethylether to give 1-(4-methyl-5-oxazolyl)-1-(3-thienyl)ethanol, m.p. 87-89°C.

¹H Nmr (CDCl₃) 1.93 (3H, s), 2.0 (3H, s), 7.05 (1H, m), 7.2-7.35 (2H, m) and 7.66 (1H, s) ppm.

¹³C Nmr (CDCl₃) 12.2, 29.3, 71.0, 120.8, 125.9, 126.3, 131.0 146.9, 148.5 and 149.3 ppm.

Found: C, 57.2; H, 5.3; N, 6.6; S, 15.1. C₁₀H₁₁NO₂S requires C, 57.4; H, 5.3; N, 6.7; S, 15.3%

EXAMPLE 3

1-(4-Methyl-5-oxazolyl)-1-(2-thienyl)ethanol

Thiophene (3.36g) in dry tetrahydrofuran (20ml) was stirred and cooled to -40°C under a dry nitrogen atmosphere and n-butyllithium (2.5M solution in hexane, 16ml) was added dropwise. The mixture was allowed to warm to -20°C and then after 1 hour was cooled to -70°C. 5-Acetyl-4-methyloxazole (5g) in dry tetrahydrofuran (15ml) was added dropwise. After a further 1 hour the mixture was allowed to warm the room temperature and was stirred for a further 2 hours. Aqueous sodium hydrogen carbonate was added and the mixture was extracted with diethylether. The material thus obtained was purified by flash chromatography to give the title compound. M.p. 84-85°C.

¹H Nmr (CDCl₃) 2.04 and 2.1 (each 3H, s), 2.87 (1H, br s), 6.96 (2H, m), 7.29 (1H, m) and 7.72 (1H, s) ppm.

Found: C, 57.1; H, 5.2; N, 6.5. C₁₀H₁₁NO₂S requires C, 57.4; H, 5.3; N, 6.7%

5

EXAMPLE 4

1-(3-Furyl)-1-(4-methyl-5-thiazolyl)ethanol

3-Bromofuran (6.8g) in diethylether (15ml) was added dropwise to n-butyllithium (2.5M solution in hexane, 18.4ml) in diethylether (20ml) at -70°C under a nitrogen atmosphere. After 1 hour, 5-acetyl-4-methylthiazole (5g) in diethylether (15ml) was added dropwise. After a further 3 hours at -70°C, the mixture was allowed to warm to room temperature and was then left overnight. The mixture was poured into water and extracted with diethylether. The product thus obtained was crystallised from diethylether, m.p. 102-104°C.

¹H Nmr (CDCl₃) 1.94 (3H, s), 2.25 (3H, s), 6.35 (1H, m), 7.35 (2H, m) and 8.47 (1H, s) ppm.

¹³C Nmr (CDCl₃) 15.9, 30.2, 69.2, 109.0, 131.9, 139.0, 139.7, 143.5, 147.3 and 149.0 ppm.

Found: C, 57.4; H, 5.4; N, 6.7. C₁₀H₁₁NO₂S requires C, 57.4; H, 5.3; N, 6.7%

25

EXAMPLE 5

1-(2,4-Dimethyl-5-oxazolyl)-1-(3-furyl)ethanol

The title compound was prepared following the general method of Example 4 but starting with 5-acetyl-2,4-dimethyloxazole. M.p. 93-95°C.

¹H Nmr (CDCl₃) 1.88 (3H, s), 2.0 (3H, s), 2.35 (3H, s), 3.5 (1H, s), 6.36 (1H, m) and 7.4 (2H, m) ppm.

¹³C Nmr (CDCl₃) 12.3, 13.6, 29.0, 68.3, 108.9, 130.8, 131.4, 138.8, 143.3, 148.4 and 158.8 ppm.

Found: C, 63.8; H, 6.4; N, 6.7. C₁₁H₁₃NO₃ requires C, 63.75; H, 6.3; N, 6.8%

35

EXAMPLE 6

1-(2,4-Dimethyl-5-thiazolyl)-1-(3-furyl)ethanol

The title compound was prepared following the general method of Example 4 but starting with 5-acetyl-2,4-dimethylthiazole. M.p. 104-105°C.

¹H Nmr (CDCl₃) 1.9 (3H, s), 2.15 (3H, s), 2.55 (3H, s), 3.85 (1H, s), 6.33 (1H, m) and 7.38 (2H, m) ppm.
¹³C Nmr (CDCl₃) 15.95, 18.5, 30.6, 69.3, 108.95, 132.1, 138.3, 138.9, 143.4, 146.25 and 161.9 ppm.
Found: C, 59.2; H, 5.9; N, 6.1; S, 14.2. C₁₁H₁₃NO₂S requires C, 59.2; H, 5.9; N, 6.3; S, 14.4%

EXAMPLE 7

1-(4-Methyl-5-thiazolyl)-1-(3-thienyl)ethanol

The title compound was prepared following the general method of Example 4 but using 3-bromothiophene. M.p. 149-151°C.

¹H Nmr (d₆-DMSO) 1.96 (3H, s), 2.16 (3H, s), 6.2 (1H, s), 7.08 (1H, m), 7.5 (2H, m) and 8.8 (1H, s) ppm.
¹³C Nmr (d₆-DMSO) 15.8, 30.5, 70.4, 120.6, 125.95, 126.8, 140.8, 146.5, 148.8 and 149.2 ppm.
Found: C, 52.9; H, 5.0; N, 6.0. C₁₀H₁₁NOS₂ requires C, 53.3; H, 4.9; N, 6.2%

The above compound in dry tetrahydrofuran was treated with dry hydrogen chloride in diethylether to give 1-(4-methyl-5-thiazolyl)-1-(3-thienyl)ethanol hydrochloride. M.p. 111-112°C.

¹H Nmr (d₆-DMSO) 2.04 and 2.26 (each 3H, s), 6.0 (br s), 7.16 (1H, m), 7.62 (2H, m) and 9.5 (1H, s) ppm.

35

EXAMPLE 8

1-(2,4-Dimethyl-5-oxazolyl)-1-(3-thienyl)ethanol

Starting with 3-bromothiophene and 5-acetyl-2,4-

dimethyloxazole and following the general method of Example 4 the title compound was prepared.

M.p. 132-133°C.

- 5 ^1H Nmr (CDCl_3) 1.86, 1.92 and 2.35 (each 3H, s), 3.23 (1H, br s) and 7.05, 7.27 and 7.31 (each 1H, m) ppm.
 ^{13}C Nmr (CDCl_3) 12.2, 13.8, 29.4, 71.0, 120.8, 126.1, 126.2, 131.3, 147.1, 148.6 and 158.9 ppm.

10

EXAMPLE 91-(2-Ethyl-4-methyl-5-oxazolyl)-1-(3-thienyl)ethanol

Starting with 3-bromothiophene and 5-acetyl-2-ethyl-4-methyloxazole and following the general method of Example 4 the title compound was prepared. M.p. 77.5-79°C.

15

^1H Nmr (CDCl_3) 1.23 (3H, t), 1.77 (3H, s), 1.9 (3H, s) 2.6 (2H, q), 5.15 (1H, s), 7.0 (1H, m) and 7.23 (2H, m) ppm.

20

^{13}C Nmr (CDCl_3) 10.7, 11.5, 20.9, 29.0, 70.1, 120.1, 125.4, 125.8, 130.3, 147.3, 148.5 and 162.6 ppm.

EXAMPLE 101-(3-Furyl)-1-(4-methyl-5-oxazolyl)propanol

25

Starting with 3-bromofuran and 4-methyl-5-propionyloxazole and following the general method of Example 4 the title compound was prepared.

^1H Nmr (CDCl_3) 0.92 (3H, t), 2.0-2.3 (2H, m), 2.15 (3H, s), 6.36 (1H, m), 7.4 (2H, m) and 7.66 (1H, s) ppm.

30

EXAMPLE 111-(2-Ethyl-4-methyl-5-oxazolyl)-1-(3-furyl)ethanol

35

Starting with 3-bromofuran and 5-acetyl-2-ethyl-4-methyloxazole and following the general method of Example 4 the title compound was prepared.

^1H Nmr (CDCl_3) 1.32 (3H, t), 1.88 and 2.04 (each 3H, s),

2.73 (2H, q), 2.82, (1H, br s), 6.38 (1H, m) and 7.4 (2H, m) ppm.

^{13}C Nmr (CDCl_3) 11.1, 12.5, 21.5, 29.1, 68.6, 108.9, 130.9, 131.4, 138.9, 143.4, 148.0 and 163.2 ppm.

5

EXAMPLE 12

1-(2,4-Dimethyl-5-oxazolyl)-1-(3-thienyl)propanol

Starting with 3-bromothiophene and 2,4-dimethyl-5-propionyloxazole and following the general method of Example 4 the title compound was prepared. Purification by preparative HPLC gave a white solid. M.p. 81-83°C

^{13}C Nmr (CDCl_3) 8.0, 12.4, 13.8, 35.1, 74.5, 124.0, 124.9, 126.8, 132.5, 147.7, 149.9 and 159.0 ppm.

Found: C, 60.6; H, 6.2; N, 5.7. $\text{C}_{12}\text{H}_{15}\text{NO}_2\text{S}$ requires C, 60.7; H, 6.4; N, 5.9%

EXAMPLE 13

1-(2,5-Dimethyl-4-oxazolyl)-1-(3-furyl)ethanol

Starting with 3-bromofuran and 4-acetyl-2,5-dimethyloxazole and following the general method of Example 4 the title compound was prepared.

^1H Nmr (CDCl_3) 1.8, 2.12 and 2.34 (each 3H, s), 3.6 (1H, br s), 6.38 (1H, m) and 7.32 (2H, m) ppm.

^{13}C Nmr (CDCl_3) 11.1, 13.6, 29.2, 68.1, 109.1, 132.1, 138.7, 142.4, 143.1 and 158.2 ppm.

EXAMPLE 14

1-(2,5-Dimethyl-4-oxazolyl)-1-(3-thienyl)ethanol

Starting with 3-bromothiophene and 4-acetyl-2,5-dimethyloxazole and following the general method of Example 4 the title compound was prepared. M.p. 83-84°C.

^1H Nmr (CDCl_3) 1.88, 1.98 and 2.35 (each 3H, s), 3.85 (1H, br s), 7.08 (1H, m) and 7.26 (2H, m) ppm.

^{13}C Nmr (CDCl_3) 10.8, 13.5, 29.6, 70.6, 120.4, 125.6,

126.4, 139.1, 142.5, 148.2 and 158.2 ppm.

EXAMPLE 15

1-(2,5-Dimethyl-3-furyl)-1-(4-methyl-5-thiazolyl)ethanol

5 4-Methylthiazole (6.51g) in dry tetrahydrofuran (50ml) was stirred under an atmosphere of dry nitrogen and cooled to -70°C and n-butyllithium (2.5M solution in hexane, 29ml) was added dropwise. After 30 minutes trimethylsilylchloride (7.14g) was added and the mixture
10 was allowed to warm to room temperature. After 30 minutes the mixture was again cooled to -70°C and n-butyllithium (2.5M solution in hexane, 29ml) was added dropwise. After 30 minutes 3-acetyl-2,5-dimethylfuran
15 (10g) was added dropwise. The mixture was stirred at -70°C for 1 hour and was then allowed to warm to room temperature. After 30 minutes, aqueous sodium hydrogen carbonate was added and the mixture was extracted with diethylether. The combined extracts were washed, dried and evaporated to give the title compound which was
20 recrystallised from diethylether. M.p. $100.5-101.5^{\circ}\text{C}$.

^1H Nmr (CDCl_3) 1.9, 2.06 and 2.24 (each 3H, s), 2.42 (1H, br s), 5.94 (1H, s) and 8.57 (1H, s) ppm.

25 Found: C, 60.6; H, 6.5; N, 5.9. $\text{C}_{12}\text{H}_{15}\text{NO}_2\text{S}$ requires C, 60.7; H, 6.4; N, 5.9%.

EXAMPLE 16

1-(2-Furyl)-1-(4-methyl-5-thiazolyl)ethanol

30 Starting with 4-methylthiazole and 2-acetylfuran and following the general method of Example 15 the title compound was prepared. M.p. $127-128^{\circ}\text{C}$.

^1H Nmr (CDCl_3) 1.97 and 2.18 (each 3H, s), 3.3 (1H, br s), 6.32, 6.39 and 7.41 (each 1H, m) and 8.56 (1H, s) ppm.

Found: C, 57.3; H, 5.2; N, 6.6. $C_{10}H_{11}NO_2S$ requires C, 57.4; H, 5.3; N, 6.7%

EXAMPLE 17

5 1-(4-Methyl-5-thiazolyl)-1-(2-thienyl)ethanol

Starting with 4-methylthiazole and 2-acetylthiophene and following the general method of Example 15 the title compound was prepared. M.p. 146.5 - 147.5°C.

10 1H Nmr ($CDCl_3$) 2.08 and 2.23 (each 3H, s), 3.14 (1H, br s), 6.96 (2H, m), 7.3 (1H, m) and 8.54 (1H, s) ppm.
Found: C, 53.0; H, 5.0; N, 6.0. $C_{10}H_{11}NOS_2$ requires C, 53.3; H, 4.9; N, 6.2%

15 The above compound in dry tetrahydrofuran was treated with dry hydrogen chloride in diethylether to give 1-(4-methyl-5-thiazolyl)-1-(2-thienyl)ethanol hydrochloride. M.p. 109.5 - 110.5°C.

20 1H Nmr (d_6 -DMSO) 1.84 and 1.95 (each 3H, s), 3.87 (br s), 6.65, 6.73 and 7.13 (each 1H, m) and 8.84 (1H, s) ppm.

EXAMPLE 18

1-(5-Thiazolyl)-1-(3-thienyl)ethanol

25 n-Butyllithium (2.5M solution in hexane, 5.6ml) in diethylether (25ml) was stirred at -70°C under a nitrogen atmosphere and 2-trimethylsilylthiazole (2g) in diethylether (25ml) was added dropwise. After 30 minutes
30 3-acetylthiophene (1.93g) in diethylether (25ml) was added dropwise. After a further 45 minutes the mixture was allowed to warm to room temperature and then left to stir for a further 1 hour. Saturated aqueous sodium hydrogen carbonate was added and the organic layer was separated. The aqueous layer was extracted with
35 diethylether. The organic layers were combined, washed, dried and evaporated and the residue was purified by flash chromatography to give the title compound as an

oil.

¹H Nmr (CDCl₃) 2.02 (3H, s), 3.82 (1H, br s), 7.07 (1H, m), 7.28 (2H, m), 7.56 (1H, s) and 8.63 (1H, s) ppm.

5 ¹³C Nmr (CDCl₃) 32.3, 71.8, 120.8, 126.0, 126.4, 139.3, 147.9, 148.3 and 152.9 ppm.

EXAMPLE 19

1-(3-Furyl)-1-(4-methyl-5-oxazolyl)ethene

10 1-(3-Furyl)-1-(4-methyl-5-oxazolyl)ethanol (900mg) in dry chloroform was treated with 1M anhydrous hydrogen chloride in diethylether (1.1 equivalents). After 10 minutes at room temperature, aqueous sodium hydrogen carbonate was added and the mixture was extracted with
15 dichloromethane. The material thus obtained was purified by flash chromatography to give the title compound as an almost colourless liquid.

¹H Nmr (CDCl₃) 2.22 (3H, s), 5.42 and 5.59 (each 1H, s),
20 6.55 and 7.44 (each 1H, m) and 7.52 and 7.81 (each 1H, s) ppm.

¹³C Nmr (CDCl₃) 13.0, 109.2, 115.0, 123.9, 128.1, 133.2, 140.9, 143.2, 145.4 and 148.9 ppm.

25

EXAMPLE 20

1-(3-Furyl)-1-(4-methyl-5-oxazolyl)-1-propene

Starting from 1-(3-furyl)-1-(4-methyl-5-oxazolyl)propanol and following the method of Example 19 the title compound
30 was obtained as a mixture of E and Z isomers.

¹H Nmr (CDCl₃) 1.8 and 1.92 (total 3H, d), 2.02 and 2.12 (total 3H, s), 6.1-6.3 (total 1H, m), 6.37 and 6.5 (total 1H, m), 7.18 and 7.43 (total 1H, s), 7.38 and 7.5 (total 1H, m) and 7.74 and 7.89 (total 1H, s) ppm.

35

EXAMPLE 21

1-(2,4-Dimethyl-5-oxazolyl)-1-(3-furyl)ethene Hydrochloride

5 1-(2,4-Dimethyl-5-oxazolyl)-1-(3-furyl)-1-methoxyethane (790mg) in dry diethylether was treated with 1M anhydrous hydrogen chloride in diethylether (1.2 equivalents). The title compound was obtained as a white solid which was filtered off, washed and dried. M.p. 128.5-130°C

10 ¹³C Nmr (d₆-DMSO) 12.7, 13.7, 109.5, 114.8, 123.8, 127.8, 132.7, 141.5, 144.0, 144.6 and 159.7 ppm.
Found: C, 58.3; H, 5.3; N, 5.9. C₁₁H₁₁NO₂.HCl requires C, 58.5; H, 5.4; N, 6.2%

15

EXAMPLE 22

1-(2-Furyl)-1-(4-methyl-5-oxazolyl)ethanol

5-Acetyl-4-methyloxazole (4g) in dry diethylether was added dropwise to a stirred solution of 2-lithiofuran (1 equivalent) in diethylether at -20°C. The mixture was
20 allowed to warm to room temperature and was then left overnight. Work-up and flash chromatography then gave the title compound as a white solid, m.p. 73-75°C.

¹H Nmr (CDCl₃) 1.93 and 1.95 (each 3H, s), 2.92 (1H, s),
25 6.30 (1H, m), 6.38 (1H, m), 7.41 and 7.71 (each 1H, s) ppm.

EXAMPLE 23

1-(2,4-Dimethyl-5-thiazolyl)-1-(3-pyridyl)ethanol

30 5-Acetyl-2,4-dimethylthiazole (2.5g) in dry diethylether (10ml) was added dropwise to a stirred solution of 3-lithiopyridine (from 3.5g 3-bromopyridine) in diethylether at -70°C. After 3 hours the mixture was allowed to warm to room temperature. After a further 1
35 hour, aqueous sodium hydrogen carbonate was added and the organic layer was separated. The aqueous layer was extracted with diethylether. The material obtained from

the combined organic layers was purified by flash chromatography to give the title compound, m.p. 107.5-109°C.

5 ^{13}C Nmr (CDCl_3) 16.3, 18.7, 32.7, 71.9, 123.1, 133.5, 137.9, 142.4, 146.9, 148.0 and 162.2 ppm.

EXAMPLE 24

1-(2,4-Dimethyl-5-thiazolyl)-1-(2-pyridyl)ethanol

10 Using the general method of Example 23 but using 2-lithiopyridine, the title compound was obtained.
M.p. 104-105°C.

15 ^{13}C Nmr (CDCl_3) 16.2, 18.8, 31.9, 72.5, 120.1, 122.4, 136.9, 137.2, 147.3, 148.6, 161.8 and 163.5 ppm.

EXAMPLE 25

1-(3,5-Dimethyl-4-isoxazolyl)-1-(3-furyl)ethanol

20 The title compound was prepared following the general method of Example 4 but starting with 4-acetyl-3,5-dimethylisoxazole (J.Am.Chem.Soc., 1975, 97, 6484-6491).
M.p. 88-90°C.

25 ^1H Nmr (CDCl_3) 1.83, 2.11 and 2.33 (each 3H, s), 6.33 and 7.38 (each 1H, dd) and 7.42 (1H t) ppm.

EXAMPLE 26

1-(3,5-Dimethyl-4-isoxazolyl)-1-(3-thienyl)ethanol

30 The title compound was prepared following the general method of Example 4 but starting with 4-acetyl-3,5-dimethylisoxazole and 3-bromothiophene.
M.p. 93.5-95°C.

35 ^{13}C Nmr (CDCl_3) 11.8, 12.7, 30.3, 70.1, 119.3, 120.8, 126.4, 126.5, 148.4, 158.9 and 164.8 ppm.

EXAMPLE 27

1-(2,4-Dimethyl-5-oxazolyl)-1-(3-furyl)ethyl Methyl Ether

1-(3-Furyl)-1-(2,4-dimethyl-5-oxazolyl)ethanol (2g) in dry N,N-dimethylformamide (15ml) was added to a stirred suspension of sodium hydride (80%, 300mg) in dry N,N-dimethylformamide (10ml) at 0°C. After 20 minutes, methyl iodide (1.5g) was added dropwise. The mixture was allowed to warm to room temperature and after 30 minutes aqueous sodium hydrogen carbonate was added.

The mixture was then evaporated to dryness. The residue was treated with water and extracted with diethyl ether. The material thus obtained was purified by flash chromatography to give the title compound.

¹³C Nmr (CDCl₃) 12.5, 13.8, 24.8, 50.9, 73.4, 109.3, 129.1, 132.7, 139.7, 143.1, 146.5 and 159.2 ppm.

EXAMPLE 28

1-(3-Furyl)-1-(4-methyl-5-oxazolyl)ethyl Methyl Ether

The title compound was prepared from 1-(3-furyl)-1-(4-methyl-5-oxazolyl)ethanol using the general method of Example 27.

¹H Nmr (CDCl₃) 1.81, 2.14 and 3.16 (each 3H, s), 6.32 and 7.74 (each 1H, br s) and 7.4 (1H, m)ppm.

EXAMPLE 29

1-(2-Thiazolyl)-1-(2-thienyl)ethanol

n-Butyllithium (2.5M solution in hexanes, 13.4ml) in dry diethyl ether (25ml) was added dropwise to a stirred solution of 2-bromothiazole (5g) in diethyl ether (50ml) at -70°C under an atmosphere of dry nitrogen. After 30 minutes, 2-acetylthiophene (3.85g) in diethyl ether (25ml) was added dropwise. After a further 1 hour the mixture was allowed to warm to room temperature and was left stirring overnight. Water was added.

The mixture was extracted with diethyl ether to give the

title compound which was recrystallised from diethyl ether.
M.p. 112-113°C.

5 ^{13}C Nmr (CDCl_3) 31.6, 74.8, 119.7, 124.1, 125.3, 126.8,
142.2, 150.5 and 177.1 ppm.

10 Following the general method of Example 29 and using
the appropriate ketone, the compounds of Examples 30 to
35 were prepared.

EXAMPLE 30

1-(2-Furyl)-1-(2-thiazolyl)ethanol

M.p. 91-92°C.

15 ^{13}C Nmr (CDCl_3) 28.3, 72.7, 106.4, 110.3, 119.7, 142.1,
142.4, 156.6 and 175.4 ppm.

EXAMPLE 31

1-(2-Thiazolyl)-1-(3-thienyl)ethanol

20 M.p. 107-108°C.

^{13}C Nmr (CDCl_3) 30.6, 74.6, 119.3, 121.1, 126.0, 126.1,
142.2, 147.3 and 177.8 ppm.

Hydrochloride, M.p. 120-122°C.

25 ^{13}C Nmr (d_6 -DMSO) 30.2, 73.8, 120.2, 120.6, 125.9, 126.3,
141.1, 148.1 and 179.8 ppm.

EXAMPLE 32

1-(1-Methyl-2-pyrrolyl)-1-(2-thiazolyl)ethanol

30 M.p. 143-144°C.

^{13}C Nmr (CDCl_3) 31.8, 35.4, 72.9, 106.3, 108.4, 119.9,
124.9, 134.2, 141.7 and 177.6 ppm.

EXAMPLE 33

35 1-(2-Benzofuranyl)-1-(2-thiazolyl)ethanol

M.p. 120-121°C.

^{13}C Nmr (CDCl_3) 28.3, 73.2, 103.0, 111.3, 119.9, 121.3,

122.9, 124.5, 128.0, 142.1, 155.0, 159.3 and 174.7 ppm.

EXAMPLE 34

1-(2-Thiazolyl)-1-(3-thienyl)-2,2,2-trifluoroethanol

5 M.p. 96-97°C.

Found: C, 40.6; H, 2.1; N, 5.2. $C_9H_6F_3NO_2S$
requires C, 40.75; H, 2.3; N, 5.3%

EXAMPLE 35

10 1-(3-Furyl)-1-(2-thiazolyl)-2,2,2-trifluoroethanol

M.p. 106-107°C.

Found: C, 43.6; H, 2.3; N, 5.5. $C_9H_6F_3NO_2S$
requires C, 43.4; H, 2.4; N, 5.6%

EXAMPLE 36

15 1-(4,5-Dimethyl-2-thiazolyl)-1-(2-thienyl)ethanol

20 n-Butyllithium (2.5M solution in hexanes, 9.7ml) was added dropwise to a stirred solution of 4,5-dimethylthiazole (2.5g) in dry diethyl ether (30ml) at -70°C under an atmosphere of dry nitrogen. After 30 minutes, 2-acetylthiophene (3.1g) in diethyl ether (20ml) was added dropwise. After a further 1 hour the mixture was allowed to warm to room temperature and was then worked up in the normal fashion to yield the title
25 compound.

M.p. 129-130°C.

^{13}C Nmr ($CDCl_3$) 11.2, 14.6, 31.6, 74.3, 123.9, 124.9, 126.6, 127.2, 147.3, 151.2 and 171.7 ppm.

30

EXAMPLE 37

2-(4-Methyl-2-thiazolyl)-2-(2-thienyl)tetrahydrofuran

35 The title compound was prepared from 4-methylthiazole and 4-chloro-1-(2-thienyl)-1-butanone, using the general method of Example 36.

M.p. 59-60°C.

¹³C Nmr (CDCl₃) 17.4, 26.2, 41.2, 69.3, 86.2, 113.9, 124.2, 124.7, 126.8, 148.9, 153.1 and 175.6 ppm.

EXAMPLE 38

5 1-(4,5-Dimethyl-2-thiazolyl)-1-(3-thienyl)-2,2,2-trifluoroethanol

Starting with 3-(2,2,2-trifluoroacetyl)thiophene and using the general method of Example 36, the title compound was prepared.

10 M.p. 90-92°C.

Found: C, 45.1; H, 3.2; N, 4.6. C₁₁H₁₀F₃NOS₂ requires C, 45.0; H, 3.4; N, 4.8%

15 Following the general method of Example 4 and using the appropriate ketone, the compounds of Examples 39 to 45 were prepared.

EXAMPLE 39

20 1-(3-Furyl)-1-(3-methyl-5-isoxazolyl)ethanol

¹³C Nmr (CDCl₃) 11.3, 28.4, 68.5, 101.2, 108.5, 130.2, 139.0, 143.3, 159.6 and 175.9 ppm.

EXAMPLE 40

25 1-(3-Furyl)-1-(5-methyl-3-isoxazolyl)ethanol

M.p. 49-52°C.

¹³C Nmr (CDCl₃) 12.2, 29.1, 68.7, 99.8, 108.7, 131.4, 138.8, 143.3, 169.3 and 169.6 ppm.

EXAMPLE 41

30

1-(3-Furyl)-1-(4-trifluoromethyl-5-thiazolyl)ethanol

M.p. 84-85°C.

¹H Nmr (CDCl₃) 1.95 (3H, s), 3.15 (1H, s), 6.27 (1H, m), 7.32 (2H, m) and 8.56 (1H, s) ppm.

35

EXAMPLE 42

1-Cyclopropyl-1-(3-furyl)-1-(4-methyl-5-oxazolyl)methanol

M.p. 85-86°C.

¹³C Nmr (CDCl₃) 1.3, 1.5, 12.5, 20.4, 70.3, 109.3, 129.9,
131.5, 139.8, 143.2, 148.4 and 148.6 ppm.

EXAMPLE 43

2,2-Dimethyl-1-(2,4-dimethyl-5-oxazolyl)-1-(3-furyl)-1-propanol

M.p. 163-164°C.

¹³C Nmr (CDCl₃) 13.2, 13.8, 25.3, 40.2, 78.2, 111.0,
128.6, 132.9, 140.3, 141.8, 147.3 and 158.4 ppm.

EXAMPLE 44

1-(2,4-Dimethyl-5-oxazolyl)-1-(3-furyl)-2-methyl-1-propanol

¹³C Nmr (CDCl₃) 12.6, 13.8, 16.9, 36.9, 75.3, 109.3,
129.5, 132.0, 139.6, 142.8, 148.0 and 158.9 ppm.

EXAMPLE 45

1-(3-Furyl)-1-(4-methyl-2-oxazolyl)-2,2,2-trifluoroethanol

¹H Nmr (CDCl₃) 2.18 (3H, s), 6.16 (1H, s) and 6.67, 7.42,
7.46 and 7.68 (each 1H, m) ppm.

EXAMPLE 46

1-(4-Methyl-2-oxazolyl)-1-(3-thienyl)ethanol

Following the general method of Example 2 and using 2-acetyl-4-methyloxazole, the title compound was obtained.

¹³C Nmr (CDCl₃) 11.4, 28.5, 71.7, 120.8, 125.7, 126.1,
134.8, 136.3, 146.1 and 166.8 ppm.

EXAMPLE 47

1-(2-Benzofuranyl)-1-(4-methyl-5-thiazolyl)ethanol

n-Butyllithium (2.5M solution in hexane, 1 equivalent) was added dropwise to a solution of 4-methyl-2-trimethylsilylthiazole (1 equivalent) in dry diethyl ether at -70°C under an atmosphere of dry nitrogen. After 30 minutes, 2-acetylbenzofuran (1 equivalent) in diethyl ether was added. After 1 hour the mixture was allowed to warm to room temperature and was then quenched by the addition of saturated aqueous sodium hydrogen carbonate. Work up in the normal fashion and column chromatography on silica gel then afforded the title compound.
M.p. 139-140°C.

Found: C, 64.65; H, 5.0; N, 5.3. $C_{14}H_{13}NO_2S$ requires C, 64.85; H, 5.1; N, 5.4%

Following the general method of Example 47 and using the appropriate ketone, the compounds of Examples 48 to 50 were prepared.

EXAMPLE 48

1-(5-Methyl-2-furyl)-1-(4-methyl-5-thiazolyl)ethanol

M.p. 120-123°C.

^{13}C Nmr ($CDCl_3$) 13.4, 15.8, 28.5, 70.3, 106.2, 107.5, 138.3, 147.9, 149.3, 152.3 and 155.0 ppm.

EXAMPLE 49

1-(1-Methyl-3-pyrrolyl)-1-(4-methyl-5-thiazolyl)ethanol

M.p. 116-117°C.

^{13}C Nmr ($CDCl_3$) 16.2, 30.2, 36.4, 70.9, 106.5, 119.2, 122.2, 130.4, 141.4, 147.0 and 148.5 ppm.

EXAMPLE 50

2-(4-Methyl-5-thiazolyl)-2-(2-thienyl)tetrahydrofuran

Using 4-chloro-1-(2-thienyl)-1-butanone.

¹H Nmr (CDCl₃) 2.0-2.16 (2H, m), 2.33 (3H, s), 2.5-2.62 and 2.68-2.8 (each 1H, m), 4.06 (2H, m), 6.9 (2H, m), 7.24 (1H, m) and 8.57 (1H, s) ppm.

- 5 Following the general method of Example 27 and using the appropriate alcohol, the compounds of Examples 51 to 53 were prepared.

EXAMPLE 51

- 10 1-(2,4-Dimethyl-5-oxazolyl)-1-(3-furyl)ethyl Ethyl Ether
¹³C Nmr (CDCl₃) 12.4, 13.8, 15.5, 25.4, 58.6, 72.9, 109.3, 129.5, 132.4, 139.5, 143.0, 146.9 and 158.9 ppm.

EXAMPLE 52

- 15 1-(2-Thiazolyl)-1-(2-thienyl)ethyl Methyl Ether
¹³C Nmr (CDCl₃) 25.3, 51.3, 79.8, 119.5, 125.5, 125.7, 126.5, 142.3, 147.8 and 176.2 ppm.

EXAMPLE 53

- 20 1-(4-Methyl-5-thiazolyl)-1-(2-thienyl)ethyl Methyl Ether
M.p. 49-50°C.

Found: C, 55.1; H, 5.2; N, 5.8. C₁₁H₁₃NOS₂
requires C, 55.2; H, 5.5; N, 5.85%

25

The compounds of Example 54 to 57 were prepared by acid-catalysed dehydration of the corresponding tertiary alcohols using methodology analogous to that employed in Examples 19 to 21.

30

EXAMPLE 54

- 1-(3,5-Dimethyl-4-isoxazolyl)-1-(3-thienyl)ethene
M.p. 35-36°C.
Found: C, 64.5; H, 5.4; N, 6.7. C₁₁H₁₁NOS
35 requires C, 64.4; H, 5.4; N, 6.8%

EXAMPLE 55

1-(2,4-Dimethyl-5-thiazolyl)-1-(1-methyl-2-pyrrolyl)ethene

5 ^{13}C Nmr (CDCl_3) 15.5, 19.0, 34.7, 107.5, 110.2, 117.5, 123.9, 131.7, 132.0, 133.4, 148.8 and 163.3 ppm.

EXAMPLE 56

1-(1-Methyl-3-pyrrolyl)-1-(4-methyl-5-thiazolyl)ethene

10 ^{13}C Nmr (CDCl_3) 16.1, 36.2, 106.6, 112.7, 121.2, 122.7, 125.1, 131.9, 133.6, 149.8 and 149.9 ppm.

EXAMPLE 57

1-(2,4-Dimethyl-5-oxazolyl)-1-(3-furyl)-2-methyl-1-propene Hydrochloride

15 M.p. 125-126°C.

^{13}C Nmr (CDCl_3) 9.2, 13.4, 22.6, 23.1, 111.0, 112.1, 122.0, 125.4, 141.3, 143.4, 145.0, 149.4 and 162.4 ppm.

EXAMPLE 58

20 1-(2-Furyl)-1-(1,3,5-trimethyl-4-pyrazolyl)ethanol

4-Bromo-1,3,5-trimethylpyrazole was converted into the corresponding 4-lithio compound which was then reacted in situ with 2-acetylfuran.

M.p. 102-105°C.

25 Found: C, 65.1; H, 7.4; N, 12.5. $\text{C}_{12}\text{H}_{16}\text{N}_2\text{O}_2$ requires C, 65.4; H, 7.3; N, 12.7%

EXAMPLE 59

30 1-(2,4-Dimethyl-5-oxazolyl)-1-(3-furyl)-2,2,2-trifluoroethanol

Tetrabutylammonium fluoride (250mg) was added to a stirred solution of 2,4-dimethyl-5-oxazolyl 3-furyl ketone (1.7g) and (trifluoromethyl)trimethylsilane (1.9g) in dry tetrahydrofuran (30ml) at -10°C. The mixture was
35 allowed to warm to room temperature. After 45 minutes 6M hydrochloric acid (30ml) was added. After 1 hour the

mixture was basified by the addition of saturated aqueous sodium hydrogen carbonate and then extracted with dichloromethane. The material thus obtained was purified by flash chromatography and recrystallisation from diethyl ether.

M.p. 129-130.5°C.

Found: C, 50.45; H, 3.7; N, 5.3. $C_{11}H_{10}F_3NO_3$ requires C, 50.6; H, 3.9; N, 5.4%

EXAMPLE 60

1-(2,4-Dimethyl-5-thiazolyl)-1-(1-methyl-2-pyrrolyl)ethanol

n-Butyllithium (2.5M solution in hexanes, 20ml) in dry diethyl ether was cooled to -70°C under dry nitrogen and TMEDA (5.8g) was added. After 5 minutes, 1-methylpyrrole (5.4g) in diethyl ether was added dropwise. After a further 15 minutes, 5-acetyl-2,4-dimethylthiazole (4.5ml) was added dropwise. After 30 minutes the mixture was allowed to warm to room temperature and was then worked up in the usual fashion.

M.p. 194-197°C (dec.).

^{13}C Nmr ($CDCl_3$) 14.4, 18.8, 31.6, 35.5, 70.7, 106.1, 108.0, 124.7, 135.0, 137.5, 145.7 and 162.5 ppm.

EXAMPLE 61

1-(5-(2-Hydroxyethyl)-4-methyl-2-thiazolyl)-1-(3-thienyl)ethanol

n-Butyllithium (2.5M solution in hexanes, 75mmoles) was added to a stirred solution of 5-(2-hydroxyethyl)-4-methylthiazole (35 mmoles) in dry tetrahydrofuran (80ml) at -70°C under an atmosphere of dry nitrogen. After 30 minutes, 3-acetylthiophene (38 mmoles) in dry tetrahydrofuran (10ml) was added dropwise. After 1 hour the mixture was allowed to warm to room temperature and was then stirred overnight. The normal work-up followed

by column chromatography then gave the title compound.
M.p. 127-129°C.

5 ^{13}C Nmr (d_6 -DMSO) 15.7, 30.3, 30.8, 62.1, 74.5, 120.9,
126.4, 127.4, 129.0, 148.0, 149.6 and 175.4 ppm.

EXAMPLE 62

1-(5-(2-Acetoxyethyl)-4-methyl-2-thiazolyl)-1-(3-thienyl)ethanol

10 The product from Example 61 was treated at room temperature with acetyl chloride in dichloromethane in the presence of triethylamine.

15 ^{13}C Nmr (CDCl_3) 14.9, 20.9, 26.0, 30.7, 64.0, 74.4, 121.1, 126.0, 126.1, 127.5, 147.5, 148.6, 170.7 and 173.7 ppm.

Found: C, 54.1; H, 5.6; N, 4.45. $\text{C}_{14}\text{H}_{17}\text{NO}_3\text{S}_2$
requires C, 54.0; H, 5.5; N, 4.5%

20

EXAMPLE 63

1-(4-Bromo-3-furyl)-1-(2,4-dimethyl-5-oxazolyl)ethanol

Following the general method of Example 1a but using 5-acetyl-2,4-dimethyloxazole and 4-bromo-3-lithiofuran (Liebigs Ann. Chem., 1986, 625-637), the title compound
25 was prepared.

M.p. 124-125°C.

^{13}C Nmr (CDCl_3) 12.3, 13.7, 27.6, 68.5, 99.0, 129.9, 132.0, 140.4, 142.7, 146.9 and 159.0 ppm.

30

EXAMPLE 64

1-(5-Methoxymethyl-4-methyl-2-thiazolyl)-1-(3-thienyl)ethanol

The title compound was prepared by following the general method of Example 36 but using 3-acetylthiophene and 5-methoxymethyl-4-methylthiazole.
35

M.p. 71-73°C.

¹³C Nmr (CDCl₃) 15.1, 30.7, 57.9, 65.9, 74.4, 121.1, 125.9, 126.0, 128.5, 147.3, 149.5 and 175.4 ppm.

EXAMPLE 65

5 1-Azido-1-(3-furyl)-1-(4-methyl-5-oxazolyl)ethane

1-(3-Furyl)-1-(4-methyl-5-oxazolyl)ethanol (1g) was suspended in benzene (4ml). Trimethylsilylazide (822 μl) was added followed by borontrifluoride diethyletherate (770 μl). The mixture was stirred overnight at room temperature, then poured into water and extracted to give the title compound.

15 ¹³C Nmr (CDCl₃) 12.4, 25.9, 59.9, 108.8, 127.4, 132.5, 139.6, 143.9, 146.1 and 149.0 ppm.

EXAMPLE 66

1-(3-Furyl)-1-(4-methyl-5-oxazolyl)ethylamine

The product from Example 65 in ethanol was hydrogenated in the presence of 10% palladium-on-charcoal to give the title compound.

20 M.p. 82.5-83.5°C.

¹³C Nmr (CDCl₃) 12.7, 29.9, 50.5, 109.0, 129.5, 132.4, 138.4, 143.3, 148.0 and 150.6 ppm.

25

EXAMPLE 67

1-Azido-1-(2-thiazolyl)-1-(3-thienyl)ethane

The title compound was obtained starting from 1-(2-thiazolyl)-1-(3-thienyl)ethanol and following the general method of Example 65.

30

¹³C Nmr (CDCl₃) 26.8, 66.2, 119.8, 122.4, 126.0, 126.6, 143.0, 143.2 and 173.4 ppm.

35

EXAMPLE 68**1-(2-Thiazolyl)-1-(3-thienyl)ethylamine**

Reduction of the product from Example 67 as in Example 66 gave the title compound.

5

¹³C Nmr (CDCl₃) 31.6, 57.4, 118.8, 120.3, 125.8, 126.0, 142.4, 148.4 and 179.7 ppm.

EXAMPLE 69

10 **1-(2,4-Dimethyl-5-oxazolyl)-1-(3-furyl)-2,2,2-trifluoroethylamine**

1-(2,4-Dimethyl-5-oxazolyl)-1-(3-furyl)-2,2,2-trifluoroethanol (160mg) was suspended in benzene (2ml) at room temperature. Diphenylphosphoryl azide (156μl) was added, followed by 1,8-diazabicyclo [5.4.0] undec-7-ene (112μl). The mixture was stirred for 20 hours and was then diluted with ethyl acetate and water. Work-up in the usual fashion then gave 1-azido-1-(2,4-dimethyl-5-oxazolyl)-1-(3-furyl)-2,2,2-trifluoroethane. Reduction of this azide using the method of Example 66 then gave the title compound.

15

20

25

¹³C Nmr (CDCl₃) 12.4, 13.8, 58.0, (q, J 30Hz), 109.9, 122.8, 125.7, (q, J 286Hz), 135.0, 141.0, 141.3, 143.4 and 159.8 ppm.

EXAMPLE 70**N-[1-(1-(3-Furyl)-1-(4-methyl-5-oxazolyl)ethyl)]acetamide**

The product from Example 66 was treated with acetyl chloride in the presence of triethylamine to give the title compound.

30

35

¹³C Nmr (CDCl₃) 12.6, 23.8, 25.6, 52.5, 108.9, 129.4, 130.8, 139.5, 143.6, 147.1 148.0 and 168.9 ppm.

PHARMACY EXAMPLES

The following examples illustrate suitable pharmaceutical compositions to be used in the method of the invention.

5

Composition 1 - Tablets

	Compound of Example 5	10g
	Lactose	94g
	Microcrystalline cellulose	86g
10	Polyvinylpyrrolidone	8g
	Magnesium stearate	2g

15 The compound of Example 5, lactose, cellulose and polyvinylpyrrolidone are sieved and blended. The magnesium stearate is sieved and then blended into the above mixture. Compression using suitable punches then yields 1000 tablets each containing 10mg of the active ingredient. If desired, the obtained tablets can then be film coated.

20

Composition 2 - Tablets

	Compound of Example 46	50g
	Lactose	80g
	Microcrystalline cellulose	20g
25	Potato starch	40g
	Polyvinylpyrrolidone	8g
	Magnesium stearate	2g

30 The compound of Example 46, lactose, cellulose and part of the starch are mixed and granulated with 10% starch paste. The resulting mixture is dried and blended with the remaining starch, the polyvinylpyrrolidone and the sieved magnesium stearate. The resulting blend is then compressed to give 1000 tablets each containing 50mg of
35 the active ingredient.

Composition 3 - Capsules

Compound of Example 31	100g
Pregelatinised starch	98g
Magnesium stearate	2g

5

The compound of Example 31 and the starch are sieved, blended together and then lubricated with the sieved magnesium stearate. The blend is used to fill 1000 hard gelatine capsules of a suitable size. Each capsule contains 100mg of the active ingredient.

10

Composition 4 - Injection Formulation

Compound of Example 66	0.5 to 10g
Polyethoxylated castor oil	15g
Water for injection ad	100g

15

Sodium chloride may be added to adjust the tonicity of the solution and the pH may be adjusted to that of maximum stability and/or facilitate solution of the compound of the invention using dilute acid or alkali or by the addition of suitable buffer salts. Antioxidants and metal chelating salts may also be included.

20

The solution is prepared, clarified and filled into appropriate size bottles and sealed. The formulation is sterilised by heating in an autoclave. Alternatively, the solution may be sterilised by filtration and filled into sterile bottles under aseptic conditions. The solution may be packed under a nitrogen blanket.

25

30

Composition 5 - Injection Formulation

Compound of Example 5	0.5 to 10g
Polyethoxylated castor oil	15g
Propylene glycol	20g
Polyoxyethylene-polyoxypropylene block copolymer (Pluronic F68)	10g

35

Water for injection ad 100g

5 The compound of the invention is added to a mixture of
polyethoxylated castor oil, propylene glycol and Pluronic
F68. The mixture is gently heated until a clear solution
is obtained. This solution is sterilised by heating in
an autoclave or alternatively, by the process of
filtration. A concentrated sterile solution is thus
obtained, which is suitable for dilution with sterile
10 water in order to form a composition suitable for
parenteral administration.


Composition 6 - Injection Formulation

Compound of Example 59 0.5 to 10g
15 Hydroxypropyl- β -cyclodextrin 10g
Water for injection ad 100g

20 Water for injection is added to a mixture of the compound
of the invention and hydroxypropyl- β -cyclodextrin. The
mixture is gently stirred until a clear solution is
obtained. The solution is filled into bottles which are
then sealed and sterilised by heating in an autoclave or
alternatively, by the process of filtration.

CLAIMS

1. A compound having the general formula (1)



10

wherein: X is O, S, Se, or NR₂;


Y₁, Y₂, Y₃, Y₄ independently are N or CR₂;

15

Z is O, S, Se, NR₂ or C = N;

R₁ is one or more groups selected from H, lower alkyl, lower acyl, halogen, lower alkoxy or CF₃ or R₁ and the


20

ring  together represent a fused benzo ring optionally further substituted;

25

R₂ is H, lower alkyl, lower alkoxy-lower alkyl, hydroxy-lower alkyl, lower acyloxy-lower alkyl, aryl-lower alkyl or CF₃ and when more than one R₂ groups are present these may be selected independently;

30




wherein W is O, S, NH or N-lower alkyl,

R₃ is H, lower alkyl or lower acyl,

R₄ is lower alkyl, aryl-lower alkyl, cyclopropyl or lower perfluoroalkyl,

35


or R₃ and R₄ together form a ring



wherein n is 2, 3 or 4,

R_5 and R_6 independently are H, lower alkyl,
or aryl-lower alkyl;

with the proviso that at least one of X, Y_1 , Y_2 , Y_3 or Y_4
is nitrogen and that the ring is not
1-methyl-2-imidazolyl;




geometric and optical isomers and racemates thereof where
such isomers exist, as well as pharmaceutically
acceptable acid addition salts thereof and solvates
thereof;

and with the proviso that the following five compounds
are excluded:

- 1-(3-indolyl)-1-(2,5-dimethyl-3-pyrrolyl)ethene;
- 1-(1-methyl-2-indolyl)-1-(1-methyl-2-pyrrolyl)ethene;
- 1-(1-methyl-2-indolyl)-1-(1-methyl-2-pyrrolyl)ethanol;
- 1-(4-pyridyl)-1-(2-thiazolyl)ethanol;
- 1-(2-pyridyl)-1-(2-thiazolyl)ethanol.

2. A compound according to claim 1 having the general
formula (2)




wherein:

X is O or S;

and A, Z, R_1 and R_2 are as defined in claim 1.

3. A compound according to claim 1 having the general
formula (3)

56




wherein:

X and Z independently are O or S;

W is O;

10 and R₁, R₂, R₃ and R₄ are as defined in claim 1.

4. A compound according to claim 1 having the general formula (4)



wherein:

X and Z independently are O or S;

and R₁, R₂, R₅ and R₆ are as defined in claim 1.

25 5. A compound according to claim 1 being:

- 1-(3-furyl)-1-(4-methyl-5-oxazolyl)ethanol;
- 1-(4-methyl-5-oxazolyl)-1-(3-thienyl)ethanol;
- 1-(3-furyl)-1-(4-methyl-5-thiazolyl)ethanol;
- 1-(2,4-dimethyl-5-oxazolyl)-1-(3-furyl)ethanol;
- 30 - 1-(2,4-dimethyl-5-thiazolyl)-1-(3-furyl)ethanol;
- 1-(4-methyl-5-thiazolyl)-1-(3-thienyl)ethanol;
- 1-(2-ethyl-4-methyl-5-oxazolyl)-1-(3-thienyl)ethanol;
- 1-(2,5-dimethyl-4-oxazolyl)-1-(3-furyl)ethanol;
- 1-(4-methyl-5-thiazolyl)-1-(2-thienyl)ethanol;
- 35 - 1-(5-thiazolyl)-1-(3-thienyl)ethanol;
- 1-(3-furyl)-1-(4-methyl-5-oxazolyl)ethene;
- 1-(3-furyl)-1-(4-methyl-5-oxazolyl)-1-propene;

- 1-(2,4-dimethyl-5-oxazolyl)-1-(3-furyl)ethene;
- 1-(2-furyl)-1-(4-methyl-5-oxazolyl)ethanol;
- 1-(2-thiazolyl)-1-(2-thienyl)ethanol;
- 1-(2-thiazolyl)-1-(3-thienyl)ethanol;
- 5 - 1-(3-furyl)-1-(4-methyl-2-oxazolyl)-2,2,2-trifluoroethanol;
- 1-(4-methyl-2-oxazolyl)-1-(3-thienyl)ethanol;
- 1-(2,4-dimethyl-5-oxazolyl)-1-(3-furyl)-2,2,2-trifluoroethanol;
- 10 - 1-(3-furyl)-1-(4-methyl-5-oxazolyl)ethylamine;
- 1-(2-thiazolyl)-1-(3-thienyl)ethylamine;

or pharmaceutically acceptable acid addition salts thereof or solvates thereof.

15



6. A process for preparing a compound according to claim 1 by

20

(I) in the case where A is $\text{C} \begin{matrix} \text{OR}_3 \\ \text{R}_4 \end{matrix}$

(a) reacting a compound of general formula (5) with an organometallic derivative of general formula (6)



25




30

or (b) reacting a compound of general formula (7) with an organometallic derivative of general formula (8)

35



10 or (c) reacting a compound of general formula (9) with an organometallic derivative of general formula R_4M



20 and quenching the reaction mixture with a proton source (R_3 is H) or an alkylating (R_3 is lower alkyl) or acylating (R_3 is lower acyl) reagent;

or (d) reacting a compound of general formula (9) with a silyl derivative of general formula R_4SiMe_3 ;

25 (II) in the case where R_3 is lower alkyl or lower acyl

the compound wherein A is $\text{C} \begin{array}{l} \text{OR}_3 \\ \text{R}_4 \end{array}$ and R_3 is H may

30 be first obtained as above and then converted into the compound wherein R_3 is lower alkyl or lower acyl;

(III) in the case where A is $\text{C}=\text{C} \begin{array}{l} \text{R}_5 \\ \text{R}_6 \end{array}$

by

35

(a) elimination of HWR_3 from a compound of formula (1)

wherein A is $\begin{array}{c} \text{WR}_3 \\ | \\ \text{C} \\ | \\ \text{R}_4 \end{array}$

5 or (b) by using a compound of general formula (9) as the substrate for a standard alkene forming reaction; or

(IV) in the case where A is $\begin{array}{c} \text{NHR}_3 \\ | \\ \text{C} \\ | \\ \text{R}_4 \end{array}$
by

10

(a) using a compound of general formula (1) wherein A

is $\begin{array}{c} \text{OR}_3 \\ | \\ \text{C} \\ | \\ \text{R}_4 \end{array}$ or $\text{C}=\text{C} \begin{array}{l} \text{R}_5 \\ \text{R}_6 \end{array}$ as the substrate

15



for a Ritter reaction,

or (b) by using a compound of general formula (1) wherein
20 A is $\begin{array}{c} \text{OH} \\ | \\ \text{C} \\ | \\ \text{R}_4 \end{array}$ as the substrate for a Mitsunobu-type
reaction,

or (c) reacting a compound of general formula (1) wherein
25 A is $\begin{array}{c} \text{OR}_3 \\ | \\ \text{C} \\ | \\ \text{R}_4 \end{array}$ with trimethylsilylazide and a Lewis acid,
and then reducing the resultant azide.

7. A compound of the general formula (5) or (9)

30



35

wherein X is O, S or Se;

Y_1 is C-H, C-lower alkyl or C-CF₃;

Y_2 is N;

5 either Y_3 or Y_4 is CR₂ and the acyl group is attached to the other of these positions;

R_4 is C₂ to C₆ alkyl or perfluoroalkyl;

and R_1 , R_2 and Z are as defined above

10 with the provisos that when X is O, the acyl group is not attached to Y_3 and that the following four compounds are excluded:

ethyl 4-thiazolyl ketone;


tert-butyl 5-thiazolyl ketone;

tert-butyl 5-oxazolyl ketone;

15 tert-butyl 4-tert-butyl-2-methyl-5-oxazolyl ketone.

8. A pharmaceutical formulation containing a compound having the general formula (1)

20



25 wherein: X is O, S, Se, or NR₂;

Y_1 , Y_2 , Y_3 , Y_4 independently are N or CR₂;

Z is O, S, Se, NR₂ or C = N;

30

R_1 is one or more groups selected from H, lower alkyl, lower acyl, halogen, lower alkoxy or CF₃ or R_1 and the

ring  together represent a fused benzo ring

35

optionally further substituted;

R_2 is H, lower alkyl, lower alkoxy-lower alkyl, hydroxy-lower alkyl, lower acyloxy-lower alkyl, aryl-lower alkyl or CF_3 and when more than one R_2 groups are present these may be selected independently;

5

and A is $\begin{array}{c} WR_3 \\ | \\ C \\ | \\ R_4 \end{array}$ or $\begin{array}{c} R_5 \\ | \\ C=C \\ | \\ R_6 \end{array}$

wherein W is O, S, NH or N-lower alkyl,

10


R_3 is H, lower alkyl or lower acyl,

R_4 is lower alkyl, aryl-lower alkyl,

cyclopropyl or lower perfluoroalkyl,

or R_3 and R_4 together form a ring


15



R_5 and R_6 independently are H, lower alkyl, or aryl-lower alkyl;

with the proviso that at least one of X, Y_1 , Y_2 , Y_3 or Y_4 is nitrogen and that the ring

20



is not 1-methyl-2-imidazolyl;

25


geometric and optical isomers and racemates thereof where such isomers exist, as well as pharmaceutically acceptable acid addition salts thereof and solvates thereof,

30

as active ingredient and a pharmaceutically acceptable carrier.

9. A compound having the general formula (1)

35



wherein: X is O, S, Se, or NR₂;

Y₁, Y₂, Y₃, Y₄ independently are N or CR₂;

5

Z is O, S, Se, NR₂ or C = N;

10

R₁ is one or more groups selected from H, lower alkyl, lower acyl, halogen, lower alkoxy or CF₃ or R₁ and the



ring  Z together represent a fused benzo ring

optionally further substituted;

15

R₂ is H, lower alkyl, lower alkoxy-lower alkyl, hydroxy-lower alkyl, lower acyloxy-lower alkyl, aryl-lower alkyl or CF₃ and when more than one R₂ groups are present these may be selected independently;


20

and A is  or 

wherein W is O, S, NH or N-lower alkyl,

25

R₃ is H, lower alkyl or lower acyl,
R₄ is lower alkyl, aryl-lower alkyl,
cyclopropyl or lower perfluoroalkyl,
or R₃ and R₄ together form a ring



30


R₅ and R₆ independently are H, lower alkyl, or aryl-lower alkyl;

with the proviso that at least one of X, Y₁, Y₂, Y₃ or Y₄ is nitrogen and that the ring

35

is not 1-methyl-2-imidazolyl;

geometric and optical isomers and racemates thereof where



such isomers exist, as well as pharmaceutically acceptable acid addition salts thereof and solvates thereof,


5 for use in therapy.

10. A compound as defined in claim 9 for use as an agent for the treatment of acute and chronic neuropsychiatric disorders characterised by progressive processes that
10 sooner or later lead to neuronal cell death and dysfunction.

11. A compound as defined in claim 10 for the treatment of stroke; cerebral ischaemia; dysfunctions resulting
15 from brain and/or spinal trauma; hypoxia and anoxia; multi-infarct dementia; AIDS dementia; neurodegenerative diseases; brain dysfunction in connection with surgery; and CNS dysfunctions as a result of exposure to neurotoxins or radiation.

20

12. The use of a compound having the general formula (1)



wherein: X is O, S, Se, or NR₂;

30

Y₁, Y₂, Y₃, Y₄ independently are N or CR₂;

Z is O, S, Se, NR₂ or C = N;

35

R₁ is one or more groups selected from H, lower alkyl, lower acyl, halogen, lower alkoxy or CF₃ or R₁ and the



ring  together represent a fused benzo ring

optionally further substituted;

5

R_2 is H, lower alkyl, lower alkoxy-lower alkyl, hydroxy-lower alkyl, lower acyloxy-lower alkyl, aryl-lower alkyl or CF_3 and when more than one R_2 groups are present these may be selected independently;

10


and A is  or 

wherein W is O, S, NH or N-lower alkyl,

15

R_3 is H, lower alkyl or lower acyl,
 R_4 is lower alkyl, aryl-lower alkyl,
 cyclopropyl or lower perfluoroalkyl,
 or R_3 and R_4 together form a ring


20

 wherein n is 2, 3 or 4,

R_5 and R_6 independently are H, lower alkyl,
 or aryl-lower alkyl;

with the proviso that at least one of X, Y_1 , Y_2 , Y_3 or Y_4
 is nitrogen and that the ring

25



is not 1-methyl-2-imidazolyl;

30


geometric and optical isomers and racemates thereof where
 such isomers exist, as well as pharmaceutically
 acceptable acid addition salts thereof and solvates
 thereof for the manufacture of a medicament for the
 treatment of acute and chronic neuropsychiatric disorders
 characterised by progressive processes that sooner or
 later lead to neuronal cell death and dysfunction.

35

13. The use according to claim 12 for the manufacture of

a medicament for the treatment of stroke; cerebral ischaemia; dysfunctions resulting from brain and/or spinal trauma; hypoxia and anoxia; multi-infarct dementia; AIDS dementia; neurodegenerative diseases; brain dysfunction in connection with surgery; and CNS dysfunctions as a result of exposure to neurotoxins or radiation.

14. A method for the treatment of acute and chronic neuropsychiatric disorders characterised by progressive processes that sooner or later lead to neuronal cell death and dysfunction by administering to a host in need of such treatment a sufficient amount of a compound having the general formula (1)



20

wherein: X is O, S, Se, or NR₂;


25

Y₁, Y₂, Y₃, Y₄ independently are N or CR₂;

Z is O, S, Se, NR₂ or C = N;

30

R₁ is one or more groups selected from H, lower alkyl, lower acyl, halogen, lower alkoxy or CF₃ or R₁ and the


ring  together represent a fused benzo ring

optionally further substituted;

35


R₂ is H, lower alkyl, lower alkoxy-lower alkyl, hydroxy-lower alkyl, lower acyloxy-lower alkyl, aryl-lower alkyl or CF₃ and when more than one R₂ groups are present these

may be selected independently;




wherein W is O, S, NH or N-lower alkyl,

R₃ is H, lower alkyl or lower acyl,
R₄ is lower alkyl, aryl-lower alkyl,
cyclopropyl or lower perfluoroalkyl,
or R₃ and R₄ together form a ring



R₅ and R₆ independently are H, lower alkyl,
or aryl-lower alkyl;

with the proviso that at least one of X, Y₁, Y₂, Y₃ or Y₄
is nitrogen and that the ring



is not 1-methyl-2-imidazolyl;

geometric and optical isomers and racemates thereof where
such isomers exist, as well as pharmaceutically
acceptable acid addition salts thereof and solvates
thereof.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/00663

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07D 413/06, C07D 417/06, C07D 417/14, C07D 263/32, C07D 277/24,
A61K 31/41, A61K 31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA, WPI

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO, A1, 9313083 (FUJISAWA PHARMACEUTICAL CO., LTD.), 8 July 1993 (08.07.93) --	1-6,8-13
X	J. Org. Chem., Volume 53, No 8, 1988, A. Dondoni et al., "Synthesis of (Trimethylsilyl)thiazoles and Reactions with Carbonyl Compounds. Selectivity Aspects and Synthetic Utility", pages 1748-1761 --	7
X	Patent Abstracts of Japan, Vol 13, No 592, C-671, abstract of JP, A, 1-249760 (YAMAHA CORP), 5 October 1989 (05.10.89) --	7



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

4 October 1994

Date of mailing of the international search report

17 -10- 1994

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Gerd Strandell
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/00663

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP, A2, 0091726 (SUMITOMO CHEMICAL COMPANY LIMITED), 19 October 1983 (19.10.83) ----- -----	1-6,8-11

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/00663

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 14
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☒ Claims Nos.: 1-4, 6-7, 8-13
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

See next sheet!
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:


Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

The wording "R₁ and the ring  together represent a fused benzo ring optionally further substituted" in claims 1-4, 6-7 and 8-13 is too broadly formulated to permit an adequate search. The search has therefore essentially been restricted to those compounds of Formula (1) which are supported by the examples.

Due to the large number of variables (X, Y₁, Y₂, Y₃, Y₄, A, Z, R₁) in Formula (1) the structures of the compounds covered by the Formula (1), will be so different from each other that there seems to exist no structural, clearly chemical and pharmaceutical relationship which forms a single inventive concept.

INTERNATIONAL SEARCH REPORT
Information on patent family members

27/08/94

International application No.

PCT/SE 94/00663

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 9313083	08/07/93	AU-A- 3171493	28/07/93
EP-A2- 0091726	19/10/83	SE-T3- 0091726	
		AU-B- 560436	09/04/87
		AU-A- 1148383	08/09/83
		CA-A- 1293249	17/12/91
		DE-A- 3378534	29/12/88
		US-A- 4618617	21/10/86